Using PARP Inhibitors in Advanced Ovarian Cancer

The approval of PARP inhibitors has caused a paradigm shift in ovarian cancer management and a challenge for clinicians, who must decide how best to use these agents in individualized treatment.

Source: CancerNetwork - July 18, 2018 Category: Cancer & Oncology Authors: Roisin E. O ’Cearbhaill, MD Source Type: news